Literature DB >> 6223710

Role of class I and class II antigens in the allogenic stimulation: class I and class II recognition in allogenic stimulation; blocking of MLR by monoclonal antibodies and F(ab')2 fragments.

J Kalil, E E Wollman.   

Abstract

Purified monomorphic monoclonal antibodies against Class I and Class II antigens in the inhibition of in vitro allogenic response were assayed. As expected, anti-Class II antibodies are highly inhibitory when used in concentrations greater than 5 micrograms/ml in MLRI and 50 micrograms/ml in MLRII. Surprisingly, anti-Class I monoclonal antibodies are as effective as anti-Class II in inhibiting primary MLR although they have no effect in MLRII. These results were confirmed by using F(ab')2 fragments. The inhibitory effect of anti-Class I has been shown to occur at the stimulator cell level. It is proposed that the allogenic stimulation is elicited after Class I and Class II recognition although only Class II differences are responsible for the proliferative response.

Mesh:

Substances:

Year:  1983        PMID: 6223710     DOI: 10.1016/0008-8749(83)90078-3

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  The role of class I histocompatibility antigens in the regulation of T-cell activation.

Authors:  J D Dasgupta; K Cemach; D P Dubey; E J Yunis; D B Amos
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

2.  Role in T-cell activation for HLA class I molecules from accessory cells: further distinction between activation signals delivered to T cells via CD2 and CD3 molecules.

Authors:  S Huet; L Boumsell; B Raynal; L Degos; J Dausset; A Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  An early postinfection signal mediated by monoclonal anti-beta 2 microglobulin antibody is responsible for delayed production of human immunodeficiency virus type 1 in peripheral blood mononuclear cells.

Authors:  P Corbeau; C Devaux; F Kourilsky; J C Chermann
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.